Stock Events

Stock Events

Bioxytran 

$0.04
4
-$0-2.86% Thursday 19:51

Statistics

Day High
0.04
Day Low
0.04
52W High
0.23
52W Low
0.03
Volume
656,000
Avg. Volume
382,835
Mkt Cap
4.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-4.73MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIXT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops drugs for life-threatening diseases, including those in areas where Bioxytran operates, making them direct competitors in the biotech and pharmaceutical space.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm focusing on human therapeutics, with products that could compete with Bioxytran's treatments in various therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for serious medical conditions, potentially overlapping with Bioxytran's market.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for creating novel therapies for treating serious diseases, which could include competitive products in the same domain as Bioxytran.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology, and while their main focus differs, their expansion into new therapeutic areas could make them a competitor to Bioxytran.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, potentially in competition with Bioxytran's products.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, and their innovative approach to drug development could position them as competitors in the same therapeutic areas as Bioxytran.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates in various therapeutic areas, including those targeted by Bioxytran, making them a broad competitor.

About

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Show more...
CEO
Dr. David Platt Ph.D.
Employees
3
Country
US
ISIN
US09075D1028

Listings

OTC Link
US
BIXT

0 Comments

Share your thoughts

FAQ

What is Bioxytran stock price today?▼
The current price of BIXT is $0.04 USD — it has decreased by -2.86% in the past 24 hours. Watch Bioxytran stock price performance more closely on the chart.
What is Bioxytran stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bioxytran stocks are traded under the ticker BIXT.
Is Bioxytran stock price growing?▼
BIXT stock has fallen by -15.19% compared to the previous week, the month change is a +1.24% rise, over the last year Bioxytran has showed a -67.7% decrease.
What is Bioxytran market cap?▼
Today Bioxytran has the market capitalization of 4.03M
What is Bioxytran revenue for the last year?▼
Bioxytran revenue for the last year amounts to 0 USD.
What is Bioxytran net income for the last year?▼
BIXT net income for the last year is -4.73M USD.
How many employees does Bioxytran have?▼
As of April 03, 2026, the company has 3 employees.
In which sector is Bioxytran located?▼
Bioxytran operates in the Health Care sector.
When did Bioxytran complete a stock split?▼
The last stock split for Bioxytran was on August 22, 2018 with a ratio of 1:30.
Where is Bioxytran headquartered?▼
Bioxytran is headquartered in Needham, US.